Provectus Pharmaceuticals to Present at “3rd Annual Cancer Immunotherapy: A Long-Awaited Reality” Conference on October 4, 2012

<0> Provectus Pharmaceuticals, Inc.Peter R. Culpepper, CFO, COO866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon Nurse, DM, SVP – Investor RelationsBill Gordon, SVP – Media Relations212-564-4700 </0>

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, ), a development-stage oncology and dermatology biopharmaceutical company, will be presenting at the " on October 4, 2012 at 11:30 a.m. EDT at the New York Academy of Medicine in New York City.

Craig Dees, PhD., Chairman and Chief Executive Officer of Provectus will discuss PV-10’s immunologic potential in treating melanoma and other cancer indications including liver, pancreatic and colorectal cancer.

PV-10 is Provectus’s novel oncology drug designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, thereby reducing potential for systemic side effects.

The presentation will be webcast and archived for future viewing. Further information about the conference and the webcast can be found at the following link:

"Cancer Immunotherapy: A Long Awaited Reality" is a unique, single-day conference event that unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, . For additional information about Provectus please visit the Company's website at or contact Porter, LeVay & Rose, Inc.

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.